Skip to Content



Treatment for Bacterial Infection

Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review

KENILWORTH, N.J., February 13, 2006 -- Schering-Plough Corporation today reported that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for garenoxacin, a new type of broad-spectrum quinolone antibiotic for treating Gram-positive and Gram-negative bacterial infections, including those caused by anaerobic organisms and resistant bacterial strains. The NDA has been granted a 10-month review by FDA.

Schering-Plough is seeking U.S. marketing approval of garenoxacin for use in treating adult patients with certain bacterial infections. The company plans to file a similar new drug application for garenoxacin with the European Medicines Agency (EMEA) this year.

Garenoxacin is a novel des-F6-quinolone antibacterial agent discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan. Schering-Plough licensed worldwide rights to develop, use and sell garenoxacin, excluding Japan, South Korea and China, in June 2004.

Posted: February 2006

Garenoxacin FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.